Compare FMC Corp (FMC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Sanofi SA — how do they compare? FMC Corp trades at $11.17 (market cap $1.36B), while Sanofi SA trades at $43.81 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 76.4× FMC Corp's market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| FMC | SNY | |
|---|---|---|
Market Cap | $1.36B | $103.94B |
Sector | Basic Materials | Health |
52-Week High | $43.90 | $52.34 |
52-Week Low | $10.72 | $41.33 |
Enterprise Value | $5.50B | $120.43B |
Dividend Yield | 2.95% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC Corporation (FMC) trades at $10.72, down 1.74% on the day, reflecting ongoing challenges despite recent strategic moves. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal significant pressure with a net income margin of -72.93% and negative ROE of -80.78% for 2025. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide rimisoxafen, providing some operational support amid financial restructuring.
The outlook remains cautious with analyst consensus leaning neutral (50% Hold) despite a $16 price target suggesting 49% upside. Key risks include persistent revenue declines, high debt levels, and negative cash flow from operations. Investment opportunity exists if new product approvals and debt reduction efforts successfully stabilize profitability, but current financial metrics indicate substantial execution risk near term.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
